Medication for Opioid Use Disorder (MOUD) in Jails Program Informational Webinar

Rachel Meade
MOUD in Jails Program Administrator

January 5, 2022
January 13, 2022
Webinar Expectations

• Everyone is muted. Double check to make sure you are muted especially if you are calling in on a phone. Please mute your line.

• If you have a question, type it into the chat box so we can share all questions and answers through the RFA process. We will take time to read and answer questions throughout the webinar.

• Everything presented today is in the RFA. The RFA is more detailed, and you will want to read over it very carefully.

• There is an encore webinar scheduled for 01/13/22, if you are here today, you do not need to attend the 2nd webinar, it will be the same information.
MOUD in Jails Program
Background and Purpose

- **RCW 71.24.599: Opioid use disorder—City and county jails—Funding.** (wa.gov)
- 2021 funding for program through **ESB5476** and **ESSB5092**
- $10 million split between FY2022 and FY2023
- Funds are to expand efforts to provide opioid use disorder medication in a jail setting
  - Tribal, city, county, and regional jails
- Continue MOUD, initiate MOUD and connect incarcerated individuals to an appropriate provider or treatment site before they are released.
## Request for Applications Timeline

<table>
<thead>
<tr>
<th>Date</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>01/13/22</td>
<td>Encore webinar presentation</td>
</tr>
<tr>
<td>01/14/22</td>
<td>Questions and comments due</td>
</tr>
<tr>
<td>01/19/22</td>
<td>Answers posted</td>
</tr>
<tr>
<td>01/28/22</td>
<td>Applications due (by 2:00 pm PST)</td>
</tr>
<tr>
<td>02/08/22</td>
<td>Announce “apparent successful applicants”</td>
</tr>
<tr>
<td>02/18/22</td>
<td>Contracts estimated to begin</td>
</tr>
<tr>
<td></td>
<td>FY2022 funding must be spent by 06/30/22</td>
</tr>
<tr>
<td></td>
<td>Less than 5 months</td>
</tr>
<tr>
<td></td>
<td>FY2023 07/01/22 – 6/30/23</td>
</tr>
</tbody>
</table>

FY2022 funding must be spent by 06/30/22

Less than 5 months
2.3 Eligibility

- County, city, regional, and tribal jails
- Organizations that can manage the MOUD program for the jail.
- Organizations that can manage the MOUD program in multiple jails effectively.
- Applicants must currently have, or be able to hire, qualified and sufficient staff to address an individual’s substance use disorder, must be able to provide FDA approved medications for opioid use disorder (e.g., buprenorphine, methadone, and/or naltrexone) or contract with the treatment facility or MOUD provider and coordinate treatment connections upon release or transfer to another facility.
3.2 Budget Development

General equipment purchases are not allowed by HCA in the Contract. Specific equipment that is crucial to the success of the execution of the project may be applied for as Supplies.

Supplement / Non-Supplanting

- Funds may be used to supplement (add to), enhance or expand existing services for program activities, but shall NOT replace (supplant) those funds that have already been appropriated for the same purpose.
- A Contractor may not use funds to defray any costs that the recipient already is obligated to pay.
- The possibility of supplanting will be the subject of careful application review, possible pre-award review, post-award monitoring, and audit of any finding.
3.3 Scope of Work

Core components of the MOUD in jails program - although these are the key components and follow the standard of care for treating OUD in a jail setting, there may be unforeseen barriers to meeting all components. Please still submit an application and share any concerns. HCA is open to discussion and funding is flexible to assist in overcoming such barriers.
3.3 Scope of Work (continued)

- FDA approved medications for opioid use disorder - available, offered, and/or continued
- Assess for OUD and risk of acute withdrawal upon intake
- Discharge plan and re-entry coordination
- Naloxone upon release
- Health equity
5. Application Contents

- Budget Narrative (20 Points)
  - Include for both FY2022 and FY2023
    - FY2023 will be reviewed and reassessed in order to implement the FY2023 contract
  - FY2022 is less than 5 months
  - Focus on startup, replenishing supplies

- Data and Evaluation Requirements (20 Points)

- Application (30 Points)

- Required Attachments (30 Points)

- Executive Order 18-03 Certification (5 Points)

TOTAL 105
5.1 Budget Narrative

- Reimbursements to be made through a performance-based contract for client services.
- The HCA DBHR will require a specific budget adjusted for the remainder of FY2022.
- Budgets for FY2023 will be reviewed for continuation of the program.
- The Applicant is to submit a fully detailed budget including staff costs and any expenses necessary to accomplish the tasks and to produce the deliverables under the contract.
- Specific tools, such as job descriptions, statements of work, final budget, and deliverables will be developed to ensure consistent practice throughout the program.
Allowable expenses

Funds can be used for the following:

- FDA approved medications for OUD; methadone, buprenorphine and/or naltrexone
- Naloxone
- Other medications such as clonidine, anti-emetics, anti-diarrheal, analgesics, etc.
- Staff time to support administration of this program including:
  - Sub-contracts with community health worker, community providers.
  - Clinical staff to administer MOUD.
  - Correctional officer and/or other jail staff who work on the MOUD program.
  - Peer and/or recovery care coordination navigators.
  - Administrative staff for program administration, contract management, data collection and reporting.
Allowable expenses (continued)

- Transportation costs for staff from external community providers to come to the jails for implementation of MOUD, for staff from external community providers to transport MOUD medications to the correctional facility, for staff from the correctional facility to transport MOUD medications from an external community partner back to the correctional facility and/or to transport incarcerated individuals to receive MOUD outside of the correctional facility.
- Technology improvements that assist with the MOUD program.
- Travel per diem, training, computers, and office supplies.
5.2 Data and Evaluation Requirements

- Participation requires performance monitoring activities, including requiring timely and accurate data reporting to HCA. All contractors receiving MOUD in jail program funding must comply with contract reporting requirements in collaboration with the HCA. Further evaluation may be conducted by HCA or a third-party who may expand on data collection from those willing to participate.

- Demonstrate in the Application the ability to coordinate data and evaluation efforts with HCA staff. HCA will work with each jail to implement a plan to collect data with minimal impact on jail staff while allowing for tracking of necessary data and evaluation of the program to demonstrate the impact of the program on incarcerated individuals and their treatment plan.
5.3 Application (questions)

- Which jail or jails are you applying for? Please list and provide collaboration letters from jail administrator.

- Describe your interest, ability, readiness, and obstacles to develop an MOUD in jails program. How will this funding support the development of the MOUD program and help to overcome barriers? (1-2 page)

- Describe the MOUD program that will be developed or expanded, and what evidence-based practices and promising practices will be integrated. Include any information on culturally relevant services.

- Describe if your program will be able to offer all 3 forms of FDA approved MOUD medications to treat opioid use disorder (buprenorphine, methadone and naltrexone containing products). If not all 3, which MOUD medications would you plan to offer? For those you will not, please share obstacles for exclusion.

- Describe the discharge coordination plan services. How will this be implemented in the jail setting?

- Describe local partners to support individuals transitioning back to the community to ensure appropriate discharge planning including partners with services providing culturally appropriate care.
5.4 Required Attachments

- Attachment 1: Letter of support by jail administrator (Required and Scored) 15 POINTS
- Attachment 2: Contract manager’s name, legal address, contract signatory and DUNS number (Required)
- Attachment 3: Intent to collaborate documentation with which MOUD provider (both referral and in jail) (Required and Scored) 15 POINTS
- Attachment 4: If more than one jail, collaboration documentation from all jails (Required only if more than one jail)
Technical Assistance and Resources

🔗 **Planning and Implementation**

- Toolkits and resources that Washington State commonly references. 

- https://www.learnabouttreatment.org/for-professionals/jails-and-prisons/ - 2020 resource created by the University of Washington Addictions, Drug and Alcohol Institute (ADAI)

- DEA X-waivered prescribers for more than 30 patients: [Federal Register :: Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder](https://www.federalregister.gov/documents/2020/09/24/2020-20529/practice-guidelines-for-the-administration-of-buprenorphine-for-treating-opioid-use-disorder) and [more how to get waivered information here: X-Waiver Training for MD/DOs, Nurses (NP/CNM/CNS/CRNA), PAs, and Medical Students to Prescribe buprenorphine - PCSS (pcssnow.org)](https://www.pcssnow.org)

🔗 **Opioid Treatment Programs (OTPs)**

- **Opioid Treatment Program (OTPs)** - is a behavioral health treatment agency which is licensed by the state and federal government, as defined in 42 CFR § 8.12, RCW 71.25.590, WAC 246-341. A OTP offers both counseling services and medical services to all clients who attend. It is the only type of outpatient treatment setting under state and federal law, where an individual can receive all three types of medication for the treatment of an Opioid Use Disorder: Methadone, Buprenorphine products (Suboxone, Subutex) and Naltrexone (Vivitrol). A client who attends the program receives their administered and dispensed medication doses directly from the OTP site, instead of a pharmacy.
Technical Assistance and Resources  
(continued)

**Prescription and Dosing**

- The Prescription Monitoring Program (PMP) is a tool to validate current controlled-substance prescriptions and dose.
- 2020 ASAM National Practice Guideline for the Treatment of Opioid Use Disorder

**Assessment Tool Samples**

- Screening and Assessment Tools Chart | National Institute on Drug Abuse (NIDA)
- Validation of a Brief Measure of Opioid Dependence: The Rapid Opioid Dependence Screen (RODS) (nih.gov)

**Naloxone**

- Overdose and Naloxone: Washington State Department of Health – find helpful information on overdose, naloxone programs, harm reduction and drug user health.
- Naloxone | Section Types | stopoverdose.org – find naloxone near you, SB 5195 WA State’s 2021 Naloxone Law, start a naloxone program and more.
- Contact Sean Hemmerle (DOH) sean.hemmerle@doh.wa.gov on how to obtain naloxone and other possible naloxone funding sources or
  - Contact Miae Aramori, aramorim@ebsi.com on how to obtain naloxone
Questions
Contact the RFA Coordinator for this RFA

Kimberly French
hcaprocurements@hca.wa.gov

Emails must have 2021HCA42 in the subject line